Search

Merck & Co Inc.

Geschlossen

BrancheGesundheitswesen

148.38 -1.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

146

Max

150.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9B

-1.3B

Verkäufe

321M

17B

KGV

Branchendurchschnitt

119.161

56.659

EPS

-0.13

Dividendenrendite

2.24

Gewinnspanne

-8.051

Angestellte

73,000

EBITDA

3.4B

1.4B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+5.04% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

2.24%

2.18%

Nächstes Ergebnis

29. Okt. 2026

Nächste Dividendenausschüttung

7. Okt. 2026

Nächstes Ex-Dividendendatum

15. Sept. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

57B

365B

Vorheriger Eröffnungskurs

149.64

Vorheriger Schlusskurs

148.38

Nachrichtenstimmung

By Acuity

30%

70%

73 / 339 Ranking in Healthcare

Merck & Co Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Sept. 2026, 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

3. Sept. 2026, 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2. Sept. 2026, 19:46 UTC

Social Media
News

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

1. Sept. 2026, 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

31. Aug. 2026, 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

28. Aug. 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

27. Aug. 2026, 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

26. Aug. 2026, 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25. Aug. 2026, 23:06 UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24. Aug. 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21. Aug. 2026, 19:31 UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20. Aug. 2026, 19:31 UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19. Aug. 2026, 23:41 UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17. Aug. 2026, 19:36 UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15. Aug. 2026, 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14. Aug. 2026, 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13. Aug. 2026, 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12. Aug. 2026, 19:56 UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11. Aug. 2026, 19:36 UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

10. Aug. 2026, 19:36 UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7. Aug. 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6. Aug. 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5. Aug. 2026, 19:43 UTC

News
Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4. Aug. 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3. Aug. 2026, 20:03 UTC

News
Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31. Juli 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30. Juli 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29. Juli 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28. Juli 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27. Juli 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

Peer-Vergleich

Kursveränderung

Merck & Co Inc. Prognose

Kursziel

By TipRanks

5.04% Vorteil

12-Monats-Prognose

Durchschnitt 157.91 USD  5.04%

Hoch 180 USD

Tief 105 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Merck & Co Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

12

Buy

5

Halten

0

Sell

Stimmung

By Acuity

73 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat